$370,000.00 in Sales Expected for Alpine Immune Sciences Inc (ALPN) This Quarter
Equities research analysts expect Alpine Immune Sciences Inc (NASDAQ:ALPN) to post $370,000.00 in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Alpine Immune Sciences’ earnings. The highest sales estimate is $500,000.00 and the lowest is $300,000.00. Alpine Immune Sciences posted sales of $130,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 184.6%. The company is expected to issue its next earnings results on Wednesday, March 27th.
According to Zacks, analysts expect that Alpine Immune Sciences will report full-year sales of $1.24 million for the current year, with estimates ranging from $710,000.00 to $1.61 million. For the next fiscal year, analysts anticipate that the business will report sales of $1.42 million, with estimates ranging from $1.00 million to $2.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Alpine Immune Sciences.
Alpine Immune Sciences (NASDAQ:ALPN) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.31). Alpine Immune Sciences had a negative return on equity of 26.00% and a negative net margin of 1,602.19%.
NASDAQ:ALPN traded down $0.01 during mid-day trading on Wednesday, reaching $4.80. The company’s stock had a trading volume of 9,821 shares, compared to its average volume of 15,467. Alpine Immune Sciences has a 1 year low of $4.61 and a 1 year high of $11.75. The firm has a market cap of $66.77 million, a PE ratio of -4.00 and a beta of 0.94. The company has a debt-to-equity ratio of 0.05, a current ratio of 20.99 and a quick ratio of 20.99.
A number of large investors have recently added to or reduced their stakes in ALPN. DRW Securities LLC raised its holdings in Alpine Immune Sciences by 138.7% in the second quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock worth $184,000 after purchasing an additional 14,143 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Alpine Immune Sciences by 122.2% in the second quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 18,052 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Alpine Immune Sciences by 20.9% in the second quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock worth $927,000 after purchasing an additional 21,124 shares in the last quarter. 56.87% of the stock is owned by institutional investors.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
See Also: Why do companies engage in swaps?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.